stage set rx acceler
esrx report ep vs street conjunct esrx
result manag disclos expect custom retent rate
exceed sell season account highest
compani histori slightli prior expect retent rate
given compani continu expect grow core adjust claim
seemingli greater visibl esrx alway
somewhat outlier pbm industri compani would talk
custom loss rate invers retent never disclos
amount gross new busi win captur given sell season determin
net win loss pbm provid histor nevertheless
esrx result strength head posit ci/ow
concern investor regard esrx busi albeit
relat rebat profit retent addit custom retent
ep rev bln ebitda mln total adjust
claim mln line street view esrx ebitda/claim increas
y/i relat transit client custom claim declin
mln y/i rev mln ebitda mln ebitda/claim
calcul ep contribut qtr
total ep core esrx claim declin mln y/i ebitda/claim
ep core busi total pg detail
guidanc updat merger close approach given ci/esrx merger
expect close end esrx provid updat guidanc
remaind trim ep rais ep
given better custom retent follow esrx disclosur
rebat profit mix lower expect believ pbm
industri cloud lift thu rais target price-to-earnings
ep view increas fundament non-merg price target
esrx quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight express script prepar
loss compani
expect cut cost de-lev top-line growth
remain challeng forese futur
upsid case see top-line growth via share gain
pbm market would expand compani
multipl unadjust ep
downsid case see compani continu
stay current path major chang
busi model would lead lower multipl
unadjust ep
script compani milnon- miltot mil milnon- revenu miltot miladj milnon- miladjust mil ebitda per ebitda per claim per miloper alloc debt alloc debt alloc debt alloc debt alloc debt alloc debt cfo go capital-expenditure invest enterpris valu cfo go capital-expenditure invest enterpris valu cfo go capital-expenditure invest enterpris valu cfo go capital-expenditure invest enterpris valu cfo go capital-expenditure invest enterpris valu cfo go capital-expenditure invest enterpris valu cfo go cfo go cfo go cfo go cfo go cfo go reposremaind normal capit prioritiesremaind normal capit prioritiesremaind normal capit prioritiesremaind normal capit prioritiesremaind normal capit prioritiesremaind normal capit prioritiesabov ratio base origin cfoabov ratio base origin cfoabov ratio base origin cfoabov ratio base origin cfotax valu initi contribut mil expens savingsenterpris valu initi contribut mil expens savingsenterpris valu initi contribut mil expens savingsenterpris valu initi contribut mil expens savingsenterpris valu initi contribut mil expens savingsenterpris valu initi contribut mil expens savingsevi contribut mil ebitdaevi contribut mil ebitdaevi contribut mil ebitdaevi contribut mil ebitdaevi contribut mil ebitdaevi contribut mil ebitdaexcl ubc evi ebitda would ubc evi ebitda would ubc evi ebitda would ubc evi ebitda would ubc evi ebitda would ubc evi ebitda would time bonu employe mil includ adj ep mil donat educ fund exclud adjust epson time bonu employe mil includ adj ep mil donat educ fund exclud adjust epson time bonu employe mil includ adj ep mil donat educ fund exclud adjust epson time bonu employe mil includ adj ep mil donat educ fund exclud adjust epsif feder tax rate drop add ep midptexpect claim growth claim growth barclay script
script quarterli revenu model process mil actualactualactualprojectedprojectedprojectedprojectedprojectedpharmaci network network specialti pharmaci specialti pharmaci adjust script growthpharmaci network network specialti pharmaci specialti pharmaci adjust script per claimpharmaci network specialti pharmaci chang yr/yrpharmaci network specialti pharmaci specialti servic pbm chang yr/yrnetwork specialti servic pbm total revenuesnetwork specialti servic pbm metricsgross profit per ebitda per claim process provid chang yr/yrgross profit per ebitda per claim process provid dispens barclay script
script quarterli incom statement ex amort one-tim ex amort one-tim addback check excl intang asset exclud rate minor net check ep fulli dilut share growth ex amort one-tim net barclay script
script annual revenu model process mil actualactualactualprojectedprojectedprojectedprojectedpharmaci network network specialti pharmaci specialti pharmaci adjust script growthpharmaci network network specialti pharmaci specialti pharmaci adjust script per claimpharmaci network specialti pharmaci chang yr/yrpharmaci network specialti pharmaci specialti servic pbm chang yr/yrnetwork specialti servic pbm total revenuesnetwork specialti servic pbm metricsgross profit per ebitda per claim process provid chang yr/yrgross profit per ebitda per claim process provid dispens barclay script
script annual incom statement ex amort one-tim ex amort one-tim addback check excl intang asset exclud rate minor net check ep fulli dilut share growth ex amort one-tim net barclay script
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
barclay bank plc and/or affili lead manag co-lead manag publicli disclos offer secur issuer
 employe non-execut director barclay bank plc and/or affili director issuer
cd barclay bank plc and/or affili market-mak debt secur issu issuer
ce barclay bank plc and/or affili market-mak equiti secur issu issuer
barclay bank plc and/or affili receiv compens invest bank servic issuer past month
 barclay bank plc and/or affili expect receiv intend seek compens invest bank servic issuer
within next month
fa barclay bank plc and/or affili benefici own class equiti secur issuer calcul accord
us regul
fb barclay bank plc and/or affili benefici own long posit class equiti secur issuer
calcul accord eu regul
fc barclay bank plc and/or affili benefici own short posit class equiti secur issuer
calcul accord eu regul
gd one analyst fundament credit coverag team member household financi interest debt
equiti secur issuer
ge one analyst fundament equiti coverag team member household financi interest debt
equiti secur issuer
 issuer benefici own class common equiti secur barclay plc
barclay bank plc and/or affili parti agreement issuer provis financi servic barclay bank plc and/or
affili
 barclay bank plc and/or affili liquid provid and/or trade regularli secur issuer and/or relat
